Journal of International Psychiatry

Objective To study the clinical effects of behavioral cognitive therapy and quetiapine fumarate in the treatment of first-episode schizophrenia (SP). Methods A total of 115 patients with SP in our hospital from January 2016 to July 2018 were enrolled. The patients were divided into two groups according to the random number table (n=58). The drug group was treated with quetiapine fumarate, and the combination group was treated with behavioral cognitive therapy and quetiapine fumarate. The adverse reactions, the symptoms before treatment and 3 months after treatment (positive symptoms, negative symptoms), cognitive function, quality of life were compared. Results After 3 months of treatment, the scores of the positive and negative scales in the combined group were lower than those in the drug group (P<0.05). After 3 months of treatment, the number of correct responses, the instantaneous memory score, and the correct classification were higher than the drug group. The number of responses was less than that of the drug group (P<0.05). After 3 months of treatment, the scores of psychological function, physical function and social function of the combined group were higher than those of the drug group (P<0.05). The combined group had dizziness, drowsiness, orthostatic hypotension. The incidence of reaction was lower than that of the drug group (P<0.05). Conclusion The behavioral cognitive therapy of SP patients with SP in the first place on the basis of quetiapine fumarate can effectively alleviate clinical symptoms, restore cognitive function, improve quality of life, and help reduce the incidence of adverse reactions.

Behavioral cognitive therapy; Schizophrenia; Quetiapine fumarate; Cognitive function; Quality of life